International journal of hematology · 2023
Real-world data of AML in Japan: results of JALSG clinical observational study-11 (JALSG-CS-11).
Наблюдательное исследованиеМногоцентровое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Usuki Kensuke, Ohtake Shigeki, Honda Sumihisa, Matsuda Mitsuhiro, Wakita Atsushi, Nawa Yuichiro, Takase Ken, Maeda Akio, Sezaki Nobuo, Yokoyama Hisayuki, Takada Satoru, Hirano Daiki, Tomikawa Tatsuki, Sumi Masahiko, Yano Shingo, Handa Hiroshi, Ota Shuichi, Fujita Hiroyuki, Fujimaki Katsumichi, Mugitani Atsuko, Kojima Kensuke, Kajiguchi Tomohiro, Fujimoto Ko, Asou Norio, Usui Noriko, Ishikawa Yuichi, Katsumi Akira, Matsumura Itaru, Kiyoi Hitoshi, Miyazaki Yasushi
Аннотация
This report covers acute myeloid leukemia (AML) results from a multicenter, prospective observational study of AML, myelodysplastic syndromes, and chronic myelomonocytic leukemia in Japan. From August 2011 to January 2016, 3728 AML patients were registered. Among them, 42% were younger than 65, and the male-to-female ratio was 1.57:1. With a median follow-up time of 1807 days (95% confidence interval [CI]: 1732-1844 days), the estimated 5-year overall survival (OS) rate in AML patients (n = 3707) was 31.1% (95% CI: 29.5-32.8%). Trial-enrolled patients had a 1.7-fold higher OS rate than non-enrolled patients (5-year OS, 58.9% [95% CI: 54.5-63.1%] vs 35.5% [33.3-37.8%], p < 0.0001). Women had a higher OS rate than men (5-year OS, 34% [95% CI; 31.4-36.7%] vs 27.7% [25.7-29.7%], p < 0.0001). The OS rate was lower in patients aged 40 and older than those under 40, and even lower in those over 65 (5-year OS for ages < 40, 40-64, 65-74, ≥ 75: 74.5% [95% CI; 69.3-79.0%] vs 47.5% [44.4-50.6%] vs 19.3% [16.8-22.0%] vs 7.3% [5.5-9.4%], respectively). This is the first paper to present large-scale data on survival and clinical characteristics in Japanese AML patients.